Aug 15
Opportunity
Clinical trial participants would like more data returned to them during and after participation in clinical trials; however, the frequency, timing and type of data returned to participants today is varied and inconsistent. This opportunity provides participants with the option of receiving their study data / results in the format and at the time they choose.
Considerations to Help Action the Opportunity
- Address individual participant data return issues early in the clinical development planning process
- Ensure security of participant privacy, confidentiality, flexibility and safety while maintaining scientific integrity and product approval timelines
- Prioritize and personalize optionality in delivery and content as best as possible
- Provide support to sites, HCPs, participants and their care partners regarding management of individual data to optimize access, inclusiveness and health equity
- Understand how digital technologies and existing cross collaborations can be optimized to facilitate interoperability of systems which collect and manage patient / participant clinical care and clinical research data
Value and Potential Benefits
- Demonstrates respect and gratitude for the participant’s contributions to scientific advancements in research and development
- Enhances patient partnerships and autonomy
- Informs patients and increases awareness about clinical trials and enhances public trust, fairness and transparency
- Improves clinical trial engagement and the participant experience, potentially facilitating recruitment and retention
- Utilizes a proactive approach to achieve operational efficiencies by being prepared for unplanned requests for individual data
- Empowers participants to be more active decision makers when it comes to the use of the data they contribute to improve health outcomes
- Reduces the burden on participants and health systems by reducing repeated testing / exams, where possible
Related Blog Posts
Redesigning Clinical Trials Using Artificial Intelligence
While tech evangelists often tout artificial intelligence (AI) as healthcare’s silver bullet, the reality in clinical trials is more complex. Adoption has been cautious, shaped as much by concerns around trust and governance as by technical hurdles. Still, beneath the surface, methodical innovation is gaining momentum. AI is beginning to reshape how trials are designed,…
How Pandemic-Era Ingenuity Fuels the Future of Clinical Trials
It’s hard to believe that just five years ago, the clinical research industry found itself scrambling to adapt overnight. The COVID-19 pandemic ground global health systems to a halt and forced us all to move faster and more collaboratively than ever before. Read the full article by Allison Cuff Shimooka from The Medicine Maker here.
Science is Moving—Clinical Trials Must Catch Up
Clinical research has never been more capable of reaching new frontiers. The science is here. The technology is here. But the approach to trial design and execution hasn’t kept pace. The clinical research ecosystem proceeds cautiously for good reasons—patient safety chief among them. But too often, we’re held back by fixed mindsets and outdated processes.…